Firmonertinib + Placebo
Phase 3RecruitingInterest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
NSCLC
Conditions
NSCLC, Adjuvant Treatment
Trial Timeline
May 28, 2025 → Apr 30, 2032
NCT ID
NCT07010419About Firmonertinib + Placebo
Firmonertinib + Placebo is a phase 3 stage product being developed by ArriVent Biopharma for NSCLC. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07010419. Target conditions include NSCLC, Adjuvant Treatment.
What happened to similar drugs?
7 of 20 similar drugs in NSCLC were approved
Approved (7) Terminated (3) Active (11)
Hype Score Breakdown
Clinical
17
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07010419 | Phase 3 | Recruiting |
Competing Products
20 competing products in NSCLC